|
Patent landscape, scope, and claims: |
Scope and Claim Construction Review of US Patent 8,722,085 (Bupropion–Naltrexone Dose-Uplift Obesity Regimen)
US 8,722,085 is a US method-of-treatment patent with tight claim boundaries around a day-by-day, week-by-week titration regimen using bupropion (about 90 mg at week 1, sustained release) plus naltrexone (about 4 mg or about 8 mg at week 1, sustained release), scaling both actives by approximate multiples (2x, 3x, 4x) across weeks 2 to 4. Dependent claims further narrow to specific oral-dosage form structures (single tablet/pill/capsule; or multilayer tablet with a rapidly dissolving intermediate layer; or combinations of multiple sustained-release forms). The enforceable core is the combination product dosing schedule for obesity, not composition per se.
What is US Patent 8,722,085 and what does it claim?
What is the invention in one line?
A dosing method for administering an obesity treatment regimen with sustained-release bupropion and sustained-release naltrexone, starting at about 90 mg bupropion with 4 mg or 8 mg naltrexone and increasing the dose weekly such that bupropion and naltrexone are approximately 2x, 3x, and 4x their week-1 amounts over weeks 2, 3, and 4.
Claim 1: the independent method claim’s hard boundaries
Claim 1 requires, in sequence:
- First week: daily unit dose comprising
- about 90 mg bupropion, and
- naltrexone selected from about 4 mg and about 8 mg.
- Second week: daily unit dose comprising bupropion + naltrexone, with
- about twice as much bupropion and about twice as much naltrexone as the first week unit dose.
- Third week: daily unit dose with
- about three times bupropion and about three times naltrexone relative to week 1.
- Fourth week: daily unit dose with
- about four times bupropion and about four times naltrexone relative to week 1.
Key scope properties
- It is a method of administering. The claims do not require a diagnosis label beyond what dependent claims add (obesity).
- It uses unit dosing and a 4-week regimen (week-by-week).
- It uses “about” quantities and multipliers that track an intended titration curve.
- It is not limited to a specific named commercial product, but dependent claims require sustained-release and specific oral form structures.
Practical dose math captured by Claim 1
Because week 1 bupropion is “about 90 mg” and week 1 naltrexone is “about 4 mg” or “about 8 mg,” the multipliers imply two alternative titration tracks:
The claims are written in relational terms (multiples of the week-1 baseline), which can capture variations so long as the relative dosing pattern remains and the week-1 anchor is met.
How narrow are the dependent claims, and which product designs do they cover?
What naltrexone baseline does Claim 2/3 cover?
- Claim 2: week-1 unit dose includes about 8 mg naltrexone.
- Claim 3: week-1 unit dose includes about 4 mg naltrexone.
These dependent claims cleanly map to Track B and Track A. They reduce evidentiary ambiguity about what “selected from the group” means in Claim 1.
What oral dosage form restrictions are imposed in Claims 4–8?
- Claim 4: week-1 unit dosage is a single oral dosage form.
- Claim 5: the single oral dosage form is selected from tablet, pill, capsule.
- Claim 6: week 2 comprises two of the single oral dosage forms.
- Claim 7: week 3 comprises three of the single oral dosage forms.
- Claim 8: week 4 comprises four of the single oral dosage forms.
Scope impact: This creates a “counting” claim geometry. Instead of requiring a specific strength change in one tablet, it allows the method to be implemented by multiplying the number of identical unit forms across weeks (1, 2, 3, 4 of the same unit dosage form per day), while preserving the dose multiples.
What formulation technology is required in Claims 9–13?
-
Claim 9: bupropion is in sustained release, and naltrexone is in sustained release.
-
Claim 10: in addition to Claim 9,
- week 1 is a single oral dosage form,
- week 2 is two of the single oral dosage forms,
- week 3 is three,
- week 4 is four.
-
Claim 11: the single oral dosage form is a multilayer tablet with
- first layer containing sustained-release bupropion,
- second layer containing sustained-release naltrexone,
- intermediate layer configured to dissolve rapidly in vivo.
-
Claim 12: sustained release can be delivered as two separate single oral dosages within each unit dosage set:
- one sustained-release bupropion single form, and
- one sustained-release naltrexone single form;
then week 2 uses two of each, week 3 uses three of each, week 4 uses four of each.
-
Claim 13: further variants of the “two-form” implementation are described through swapping among multiple sustained-release bupropion and sustained-release naltrexone single forms across weeks while preserving the 2-of, 3-of, 4-of counting structure at the unit dosage level.
Scope impact:
- Claim 9 introduces a release-profile requirement that may be outcome-determinative in design-around efforts using immediate-release or different release kinetics.
- Claim 11 is unusually specific: it requires a multilayer physical architecture and an intermediate fast-dissolve layer, which narrows that dependent claim to particular tablet constructions.
What obesity treatment hook is added in Claims 14–17?
- Claim 14: identifying the individual as obese and the administering is for treatment of obesity.
- Claim 15: adds the Claim 10 structure (sustained release + counting of single oral forms across weeks).
- Claim 16: adds the multilayer formulation requirement from Claim 11.
- Claim 17: recasts the method claim in a more complete “obese individual” format and restates the core dosing schedule plus sustained-release and oral-form structure constraints.
Scope impact: The obesity language provides a tighter “medically indicated use” framing, which is relevant for US method-of-use enforcement strategies and for the question of whether an accused use qualifies as “for treatment of obesity.”
What is the enforceable claim scope in plain terms? (Claim chart logic)
Core elements likely to drive infringement
- Two-actives combination: bupropion + naltrexone in the same administered regimen.
- 4-week titration schedule:
- week 1 anchor: ~90 mg bupropion and ~4 mg or ~8 mg naltrexone,
- weeks 2–4: daily doses with bupropion and naltrexone at ~2x, ~3x, ~4x those week-1 amounts.
- Sustained release (for Claims 9–17 and their dependents): both actives in sustained release forms.
- Oral delivery structure (for Claims 4–8 and especially 10–13): single-form or counting-based multipliers; multilayer intermediate fast-dissolve architecture for Claim 11.
- Obesity use (for Claims 14–17): labeled use/treatment indication tied to obesity.
Most likely “design-around” levers
- Change the week-1 anchor doses (the “about 90 mg” and “about 4/8 mg” thresholds).
- Break the 2x/3x/4x weekly relative pattern (even if total daily amounts are similar).
- Use a non-sustained-release profile (avoiding Claim 9).
- Use different unit-dose counting mechanics not captured by “single oral dosage form” plus “two/three/four of the single form” logic (targeting Claims 4–8, 10).
- Avoid the specific multilayer tablet with a rapidly dissolving intermediate layer (targeting Claim 11).
- Reframe use away from obesity (affects Claims 14–17).
How does this patent fit the bupropion–naltrexone obesity competitive landscape?
Why this regimen is commercially relevant
The claim structure matches a familiar obesity-titration strategy used in bupropion–naltrexone combination pharmacotherapy, where patients start low and increase weekly to improve tolerability. The patent’s emphasis on exact week-by-week multipliers and sustained-release supports a dosing regimen that can be implemented via either:
- a single multilayer tablet counted from 1 to 4 per day, or
- two separate sustained-release products counted in parallel (2-of, 3-of, 4-of for each actives).
Which competitors face exposure from regimen-based method claims?
Any branded or generic manufacturer that markets or instructs a dosing schedule that meets:
- the week-1 anchor quantities, and
- the 4-week relative escalation,
- with both actives in sustained release,
and performs administration for obesity treatment,
creates infringement exposure for method claims.
However, method claims are enforced against use/instruction pathways, including clinician prescribing and product labeling. The strength of enforcement turns on whether Orange Book-listed or label-level instructions align with the claimed regimen.
What is the patent estate around US 8,722,085 likely to look like?
How method-of-use dosing patents typically cluster
US 8,722,085 is positioned as a regimen/titration method. In practice, such estates often include parallel families covering:
- composition-level inventions (fixed-dose combinations, salts, release profiles),
- manufacturing/process claims (especially for multilayer structures),
- additional dosage strengths and titration schedules,
- device or kit packaging approaches,
- use claims for obesity and related indications.
Because your request focuses on US 8,722,085 specifically and you supplied claim text only (no publication numbers, priority data, or family members), the analysis below is limited to scope within the provided claims, not a full family mapping.
What is the litigation risk profile for this kind of claim?
Why regimen claims create straightforward infringement arguments
Regimen claims are easier to litigate when:
- the label contains a dosing schedule that is numerically identical or relationally identical, and
- the formulation is clearly sustained release, and
- the regimen is presented as intended for obesity treatment.
Where litigation often turns
- Whether the accused product’s week-1 dosing is “about” the claimed amounts.
- Whether the accused titration follows “about twice/three times/four times” the week-1 baseline in practice.
- Whether the formulation is “sustained release” for both actives as required by Claim 9 onward.
- Whether the dosage form meets the multilayer architecture in Claim 11.
Key claim-scope takeaways by dependency layer (what is protected at each level?)
| Claim level |
What must be present |
Protection character |
| Claim 1 |
4-week daily titration with week-1 anchor: ~90 mg bupropion + ~4 mg or ~8 mg naltrexone; weeks 2–4 are ~2x, ~3x, ~4x |
Broad regimen framework; no release profile requirement |
| Claims 2–3 |
week-1 naltrexone specifically ~8 mg or ~4 mg |
Clarifies two alternatives within the same regimen framework |
| Claims 4–8 |
week-1 unit dose is one oral form (tablet/pill/capsule); week 2 uses 2 of that form, week 3 uses 3, week 4 uses 4 |
Locks in dosing implementation via unit-counting |
| Claims 9–10 |
bupropion sustained release + naltrexone sustained release; and unit-counting implementation |
Adds release-profile constraint |
| Claim 11 |
multilayer tablet with bupropion SR layer, naltrexone SR layer, intermediate fast-dissolve layer |
Narrows to specific tablet architecture |
| Claims 12–13 |
two separate SR forms (bupropion SR and naltrexone SR), counted in parallel across weeks |
Captures split-pill approaches within the same titration logic |
| Claims 14–17 |
obesity identified; regimen administered for obesity treatment |
Adds indication/use framing for method-of-use enforcement |
Key Takeaways
- US 8,722,085 protects a specific 4-week, week-by-week bupropion–naltrexone titration regimen anchored at ~90 mg bupropion and ~4 mg or ~8 mg naltrexone in week 1, then escalating both actives by ~2x, ~3x, ~4x in weeks 2–4.
- The enforceable scope is strongest when the accused use involves both actives in sustained release and uses dosing instructions matching the single-form or counted multiple-form structures.
- The narrowest hook is Claim 11: a multilayer tablet with an intermediate rapidly dissolving layer, which can be a key differentiator for design-around.
- Obesity language in Claims 14–17 ties the method to an indication-based use pattern, which is relevant for infringement analysis against prescribing/labeling practices.
FAQs
-
What does “about twice as much” mean in a dosing titration method claim like US 8,722,085?
It requires a relative escalation that stays within a reasonable range of the claimed “about” multipliers when compared to the week-1 baseline.
-
Does US 8,722,085 require a specific tablet strength or does it cover counting multiple identical units?
The dependent claims (4–8, 10) expressly cover implementations where week 2 uses two of the same single oral form, week 3 uses three, and week 4 uses four.
-
Can a product avoid US 8,722,085 by changing only the week-1 naltrexone starting dose?
A change that moves week-1 naltrexone away from the claimed “about 4 mg” or “about 8 mg” anchors can undermine the regimen mapping.
-
Is sustained release required for the broadest claim?
No. Sustained release is required beginning with Claim 9 and dependent claims; Claim 1 itself does not recite sustained release.
-
What is the narrowest claim feature likely to matter most for tablet-design freedom?
Claim 11’s requirement for a multilayer tablet with an intermediate layer configured to dissolve rapidly in vivo.
References (APA)
- United States Patent No. 8,722,085. (n.d.). Claims as provided in user prompt.
More… ↓
⤷ Start Trial
|
